Activation of GPR30 inhibits cardiac fibroblast proliferation

Molecular and Cellular Biochemistry

Volumn 405, Issue 1-2, 2015, Pages 135-148

  Wang, Hao ^a   Zhao, Zhuo ^a,b   Lin, Marina ^a   Groban, Leanne ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Estrogen; Fibroblast; GPR30; Heart; Proliferation

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIMITOTIC AGENT; BROXURIDINE; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CARDIOVASCULAR AGENT; COLLAGEN; COLLAGEN TYPE 1A2; COLLAGEN TYPE 3A1; CYCLIN B1; CYCLIN D1; DISCOIDIN DOMAIN RECEPTOR 2; FIBRONECTIN; G PROTEIN COUPLED RECEPTOR 30; G1; GELATINASE A; GELATINASE B; HORMONE RECEPTOR STIMULATING AGENT; MACROPHAGE ELASTASE; MESSENGER RNA; MONOCLONAL ANTIBODY KI 67; RECEPTOR; SMALL INTERFERING RNA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG; VIMENTIN; BIOLOGICAL MARKER; CCNB1 PROTEIN, RAT; CDK1 PROTEIN, RAT; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; ESTROGEN; G PROTEIN COUPLED RECEPTOR; GPR30 PROTEIN, RAT; KI 67 ANTIGEN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL COUNTING; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; GENE SILENCING; HEART FIBROBLAST; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MITOSIS INHIBITION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; FIBROBLAST; HEART VENTRICLE; METABOLISM; OVARIECTOMY; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; BIOMARKERS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN B1; CYCLIN-DEPENDENT KINASES; ESTROGENS; FIBROBLASTS; HEART VENTRICLES; KI-67 ANTIGEN; MALE; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; VIMENTIN;

EID: 84929958673     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2405-3     Document Type: Article

References (50)

1. Correa de Sa DD, Hodge DO, Slusser JP, Redfield MM, Simari RD, Burnett JC, Chen HH (2010) Progression of preclinical diastolic dysfunction to the development of symptoms. Heart 96:528–532
2. Aljaroudi W, Alraies MC, Halley C, Rodriguez L, Grimm RA, Thomas JD, Jaber WA (2012) Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation 125:782–788
3. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC Jr, Jacobsen SJ, Rodeheffer RJ (2011) Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 306:856–863
4. Agabiti-Rosei E, Muiesan ML (2002) Left ventricular hypertrophy and heart failure in women. J Hypertens Suppl 20:S34–S38
5. Oberman A, Prineas RJ, Larson JC, LaCroix A, Lasser NL (2006) Prevalence and determinants of electrocardiographic left ventricular hypertrophy among a multiethnic population of postmenopausal women (The Women’s Health Initiative). Am J Cardiol 97:512–519
6. Cheng S, Xanthakis V, Sullivan LM, Lieb W, Massaro J, Aragam J, Benjamin EJ, Vasan RS (2010) Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Circulation 122:570–578
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605–613
9. Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J, Thomas P (2007) Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 148:3236–3245
10. Revankar CM, Mitchell HD, Field AS, Burai R, Corona C, Ramesh C, Sklar LA, Arterburn JB, Prossnitz ER (2007) Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol 2:536–544
11. Wang H, Jessup JA, Lin MS, Chagas C, Lindsey SH, Groban L (2012) Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats. Cardiovasc Res 94:96–104
12. Teng J, Wang ZY, Prossnitz ER, Bjorling DE (2008) The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. Endocrinology 149:4024–4034
13. Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM (2010) Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 17:1511–1523
14. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Andò S, Maggiolini M (2006) 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol 70:1414–1423
15. Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS, Ingraham HA (2009) Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res 69:5415–5423
16. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Andò S et al (2007) G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G1 in ovarian cancer cells. Cancer Res 67:1859–1866
17. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, Lappano R, Randey DP, Ricard D, Mauro L et al (2008) Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 149:3799–3808
18. Haas E, Bhattacharya I, Brailoiu E, Damjanović M, Brailoiu GC, Gao X, Mueller-Guerre L, Marjon NA, Gut A, Minotti R et al (2009) Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 104:288–291
19. Holm A, Baldetorp B, Olde B, Leeb-Lundberg LM, Nilsson BO (2011) The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in the S and G2 phases of the cell cycle. J Vasc Res 48:327–335
20. Olde B, Leeb-Lundberg LM (2009) GPR30/GPER1: searching for a role in estrogen physiology. Trends Endocrinol Metab 20:409–416
21. Hazell GG, Yao ST, Roper JA, Prossnitz ER, O’Carroll AM, Lolait SJ (2009) Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. J Endocrinol 202:223–236
22. Deschamps AM, Murphy E (2009) Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 297:H1806–H1813
23. Bopassa JC, Eghbali M, Toro L, Stefani E (2010) A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 298:H16–H23
24. Filice E, Recchia AG, Pellegrino D, Angelone T, Maggiolini M, Cerra MC (2009) A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat. J Physiol Pharmacol 60:3–10
25. Weil BR, Manukyan MC, Herrmann JL, Wang Y, Abarbanell AM, Poynter JA, Meldrum DR (2010) Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery 148:436–443
26. Jessup JA, Lindsey SH, Wang H, Chappell MC, Groban L (2010) Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G1 in female mRen2.Lewis rats. PLoS ONE 5:e15433
27. Zhao Z, Wang H, Jessup JA, Lindsey SH, Chappell MC, Groban L (2014) Role of estrogen in diastolic dysfunction. Am J Physiol Heart Circ Physiol 306:H628–H640
28. Campbell SE, Katwa LC (1997) Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 29:1947–1958
29. Dubey RK, Gillespie DG, Jackson EK, Keller PJ (1998) 17Beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension 31:522–528
30. Lee AA, Dillmann WH, McCulloch AD, Villarreal FJ (1995) Angiotensin II stimulates the autocrine production of transforming growth factor-beta 1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 27:2347–2357
31. Lee HW, Eghbali-Webb M (1998) Estrogen enhances proliferative capacity of cardiac fibroblasts by estrogen receptor- and mitogen-activated protein kinase-dependent pathways. J Mol Cell Cardiol 30:1359–1368
32. Lindsey SH, Chappell MC (2011) Evidence that the G protein-coupled membrane receptor GPR30 contributes to the cardiovascular actions of estrogen. Gend Med 8:343–354
33. Graham HK, Horn M, Trafford AW (2008) Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiol (Oxford) 194:3–21
34. Dai Q, Lin J, Craig T, Chou YM, Hinojosa-Laborde C, Lindsey ML (2008) Estrogen effects on MMP-13 and MMP-14 regulation of left ventricular mass in Dahl salt-induced hypertension. Gend Med 5:74–85
35. Iyer RP, Patterson NL, Fields GB, Lindsey ML (2012) The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol 303:H919–H930
36. Santiago JJ, Dangerfield AL, Rattan SG, Bathe KL, Cunnington RH, Raizman JE, Bedosky KM, Freed DH, Kardami E, Dixon IM (2010) Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev Dyn 239:1573–1584
37. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck MP, Sklar LA et al (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2:207–212
38. Blasko E, Haskell CA, Leung S, Gualtieri G, Halks-Miller M, Mahmoudi M, Dennis MK, Prossnitz ER, Karpus WJ, Horuk R (2009) Beneficial role of the GPR30 agonist G1 in an animal model of multiple sclerosis. J Neuroimmunol 214:67–77
39. Meyer MR, Field AS, Kanagy NL, Barton M, Prossnitz ER (2012) GPER regulates endothelin-dependent vascular tone and intracellular calcium. Life Sci 91:623–627
40. Watanabe T, Akishita M, He H, Miyahara Y, Nagano K, Nakaoka T, Yamashita N, Kozaki K, Ouchi Y (2003) 17 beta-estradiol inhibits cardiac fibroblast growth through both subtypes of estrogen receptor. Biochem Biophys Res Commun 311:454–459
41. Fan D, Takawale A, Lee J, Kassiri Z (2012) Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 5:15
42. Iwasaki T, Mukasa K, Yoneda M, Ito S, Yamada Y, Mori Y, Fujisawa N, Fujisawa T, Wada K, Sekihara H et al (2005) Marked attenuation of production of collagen type I from cardiac fibroblasts by dehydroepiandrosterone. Am J Physiol Endocrinol Metab 288:E1222–E1228
43. Mukherjee D, Sen S (1990) Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res 67:1474–1480
44. Xu Y, Arenas IA, Armstrong SJ, Davidge ST (2003) Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc Res 57:388–394
45. Yang X, Chen B, Liu T, Chen X (2014) Reversal of myofibroblast differentiation: a review. Eur J Pharmacol 734:83–90
46. Delbeck M, Golz S, Vonk R, Janssen W, Hucho T, Isensee J, Schäfer S, Otto C (2011) Impaired left-ventricular cardiac function in male GPR30-deficient mice. Mol Med Rep 4:37–40
47. Griffin M, Lee HW, Zhao L, Eghbali-Webb M (2000) Gender-related differences in proliferative response of cardiac fibroblasts to hypoxia: effects of estrogen. Mol Cell Biochem 215:21–30
48. Ginelli P, Bella JN (2012) Treatment of diastolic dysfunction in hypertension. Nutr Metab Cardiovasc Dis 22:613–618
49. Manson JE (2014) Current recommendations: what is the clinician to do? Fertil Steril 101:916–921
50. Howard BV, Rossouw JE (2013) Estrogens and cardiovascular disease risk revisited: the Women’s Health Initiative. Curr Opin Lipidol 24:493–499